AC BioScience Overview

  • Founded
  • 2017
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • (Cancelled)
  • Investors
  • 1

AC BioScience General Information

Description

Operator of a biotechnology company intended for the treatment of tumorous and infectious diseases. The company's products specialize in the protection of the skin and mucous membranes and therapies for the treatment of cancer and also offers ancillary services to achieve a significant increase in the survival rate of patients with specific cancers through ground-breaking scientific discovery and personalized medicine using the proprietary molecules, enabling patients to apply new vascular normalizers that help drugs to better access solid tumors and oxygenation thereby increasing the efficacy of all types of chemo and radiotherapy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • C/o Fondation EPFL Innovation Park
  • Chemin de la Dent d'Oche 1A
  • 1024 Écublens
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AC BioScience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 25-May-2020 Cancelled Generating Revenue
2. Seed Round 25-May-2020 00.000 00.000 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view AC BioScience’s complete valuation and funding history, request access »

AC BioScience Patents

AC BioScience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3782702-A1 Compounds and use thereof for the treatment of infectious diseases and cancer Pending 21-Aug-2019 0000000000 0
EP-3714883-A1 Indole containing small chemical compounds and use thereof for the non-cytotoxic and immunological treatment of cancer Withdrawn 25-Mar-2019 0000000000 0
EP-3746069-A1 Composition and use thereof against drugs induced phototoxicity Pending 01-Feb-2018 0000000000
US-20210113523-A1 Compositions for treating and/or preventing photodynamic therapy side effects Pending 01-Feb-2018 0000000000
EP-3746125-A1 Compositions for treating and /or preventing photodynamic therapy side effects Pending 01-Feb-2018 A61K31/375

AC BioScience Executive Team (3)

Name Title Board Seat Contact Info
Andreas Schläpfer Co-Founder, Chief Executive Officer & Chairman
Christian Auclair Ph.D Co-Founder & Chief Scientific Officer
Camila Flores Ph.D Chief Medical Officer, Oncology
To view AC BioScience’s complete executive team members history, request access »

AC BioScience Board Members (1)

Name Representing Role Since
Andreas Schläpfer AC BioScience Co-Founder, Chief Executive Officer & Chairman 000 0000
To view AC BioScience’s complete board members history, request access »

AC BioScience Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EPFL Innovation Park Accelerator/Incubator Minority 000 0000 000000 0
To view AC BioScience’s complete investors history, request access »